What Has Been The Historical And Current Growth Of The Non Hodgkin Lymphoma (NHL) Market?
The non hodgkin lymphoma (nhl) market has seen considerable growth due to a variety of factors.
•The market for non-hodgkin lymphoma (NHL) has experienced robust growth recently. We anticipate an increase from $10.11 billion in 2024 to $11.01 billion in 2025, showcasing a compound annual growth rate (CAGR) of 8.9%.
Factors contributing to this growth during the historic period include a higher number of NHL cases, progress in diagnostic techniques, enhancements in chemotherapy and immunotherapy, advancements in clinical research and drug development, in addition to better survival rates.
What Is The Forecast For The Non Hodgkin Lymphoma (NHL) Market By 2029?
The non hodgkin lymphoma (nhl) market is expected to maintain its strong growth trajectory in upcoming years.
• The market for non hodgkin lymphoma (NHL) is predicted to experience substantial growth in the forthcoming years, with projections indicating an increase to "$15.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%.
Factors contributing to this rise in the forecast period include an aging population, development in targeted therapies, breakthroughs in immunotherapy, precision medicine strategies, and an increase in both awareness and early detection. Key trends anticipated during the forecast period involve the emergence of biosimilars, the incorporation of next-generation sequencing, the adoption of car-t cell therapies, new chemotherapy agents, and the application of real-world evidence and outcomes research.
Which Drivers Are Accelerating Growth In The Non Hodgkin Lymphoma (NHL) Market?
The non-Hodgkin lymphoma market is projected to expand due to the high occurrence rate of the condition. Non-Hodgkin lymphoma is an immune system cancer that primarily originates in the lymphatic system. The term prevalence in this case refers to the specific count of individuals in a population currently living with or diagnosed with non-Hodgkin lymphoma. The treatment of this lymphoma primarily focuses on managing and targeting the malignant cells, thereby improving the life prognosis of patients suffering from it. For example, the American Cancer Society, a US-based health organization focusing on cancer, reported in January 2023 that non-Hodgkin lymphoma constitutes 4% of all cancer varieties, affecting around 80,550 Americans, counting 44,880 men and 35,670 women, in 2023. In addition to this, the society anticipates about 20,180 fatalities resulting from this illness in 2023. Additionally, in the year 2022, the Canadian Cancer Society, a national-level charity dedicated to cancer within Canada, speculated that non-Hodgkin lymphoma would be identified in 11,400 Canadians and predicted a fatality count of 3,000 from the same. This upward trend in non-Hodgkin lymphoma cases is a significant growth driver for its associated market.
What Are The Core Segments Of The Global Non Hodgkin Lymphoma (NHL) Market?
The non hodgkin lymphoma (NHL) market covered in this report is segmented –
1) By Type: B-Cell Lymphoma, T-Cell Lymphoma
2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users
Subsegments:
1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma
2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)
Pre-Book The Non Hodgkin Lymphoma (NHL) Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Non Hodgkin Lymphoma (NHL) Market Size?
Drug innovation developments are an emerging trend in the non-Hodgkin lymphoma market. Companies in this market are concentrating on creating new products to maintain their market position. For example, in December 2022, Genentech Inc., a biotechnology firm based in the US, gained FDA approval for Lunsumio, a revolutionary bispecific antibody for the treatment of recurrent or refractory follicular lymphoma. This antibody represents a novel category of fixed-duration cancer immunotherapy and is immediately accessible as a ready-to-use treatment option, eliminating any waiting period for patients. The FDA's approval was predicated on the encouraging outcomes from the Lunsumio Phase II GO29781 study involving individuals who had previously received extensive FL treatment, especially those at a high risk of disease progression or unresponsive to former treatments.
Who Are the Key Players in the Non Hodgkin Lymphoma (NHL) Market?
Major companies operating in the non hodgkin lymphoma (NHL) market include:
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann La Roche Ltd.
• Merck & Co. Inc.
• Eli Lilly and Co.
• Novartis AG
• GlaxoSmithKline plc
• AbbVie Inc.
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Bristol Myers Squibb Co.
• Pfizer Inc.
• Celgene Corporation
• Sanofi S.A.
• Janssen Pharmaceuticals Inc.
• Johnson & Johnson
• Biogen Idec
• Boehringer Ingelheim GmbH
• Eisai Co. Ltd.
• Gilead Sciences
• Incyte Corporation
• Karyopharm Therapeutics
• Kite Pharma Inc.
• Kyowa Hakko Kirin Co. Ltd.
• MorphoSys AG
• Nordic Nanovector ASA
• Ono Pharmaceutical Co. Ltd.
• Seattle Genetics Inc.
• Spectrum Pharmaceuticals Inc.
What are the Regional Insights into the Non Hodgkin Lymphoma (NHL) Market?
North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non-Hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
